Patents by Inventor Guoxiang XIE

Guoxiang XIE has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240369563
    Abstract: Disclosed are a biomarker combination for assessing the risk of adenoma and colorectal cancer, and the use thereof, in particular a metabolic marker for assessing the risk of adenoma and colorectal cancer of a subject, and the use thereof in the preparation of a diagnostic product for evaluating the risk of adenoma and colorectal cancer. The diagnostic marker has the characteristics of high sensitivity and specificity, has higher sensitivity and specificity for early colorectal cancer diagnosis, and can be used for the early discovery of colorectal cancer, so as to buy time for patients, allow treatment to be started as soon as possible, and improve the clinical treatment effect.
    Type: Application
    Filed: May 23, 2022
    Publication date: November 7, 2024
    Inventors: Wei Jia, Guoxiang Xie, Kejun Zhou
  • Publication number: 20240319210
    Abstract: Disclosed in the present invention is an application of conjugated bilirubin as a biomarker in preparation of a diagnosis device for evaluating a risk of neonatal biliary atresia. Also disclosed in the present invention are a bilirubin content measurement method, a stable quantitative detection reagent for bilirubin, and an application of the quantitative detection reagent for bilirubin in preparation of a kit for measuring a content of the bilirubin and evaluating a risk of biliary atresia of a subject, infant hepatitis syndrome, ?1 antitrypsin deficiency disease or Alagille syndrome. Also disclosed in the present invention are a kit for measuring the content of the bilirubin or evaluating the risk of neonatal biliary atresia, an application of the kit, a method for evaluating the risk of neonatal biliary atresia, and a device for predicting the risk of neonatal biliary atresia by using an expression level of the conjugated bilirubin.
    Type: Application
    Filed: December 20, 2021
    Publication date: September 26, 2024
    Inventors: Wei Jia, Guoxiang Xie, Kejun Zhou
  • Publication number: 20240255511
    Abstract: Provided in the present invention is a device for diagnosing liver cancer. The device determines the level of a biomarker in a biological sample of a subject to be a diagnostic indicator, wherein the level of the biomarker is selected from the level of one or more of taurocholic acid, taurochenodeoxycholic acid, glycocholic acid, glycochenodeoxycholic acid, linolelaidic acid (C18:2n6t), maltotriose, maltose and/or lactose, ?-linolenic acid, ?-alanine, sebacic acid, 2-methylvaleric acid, valeric acid, isovaleric acid and hexanoic acid, and/or the ratio of secondary bile acid to primary bile acid, and/or the ratio of glycine-conjugated primary bile acid to taurine-conjugated primary bile acid, the primary bile acid being selected from cholic acid and chenodeoxycholic acid, and the secondary bile acid comprising deoxycholic acid, lithocholic acid and ursodeoxycholic acid.
    Type: Application
    Filed: May 27, 2022
    Publication date: August 1, 2024
    Inventors: Wei Jia, Guoxiang Xie, Tianlu Chen
  • Publication number: 20220273675
    Abstract: Provided are a novel bile acid derivative for treating fatty liver disease, a pharmaceutical composition thereof, and a use in the preparation of a medicine for treating and improving diseases and symptoms mediated or caused by FXR or TGR5. The bile acid derivative of the present invention inhibits or delays the metabolism of bile acid by bacterial BSH/7? dehydroxylase in the intestine and greatly prolongs the effective survival time of bile acid in the intestine. The bile acid derivative and the pharmaceutical composition thereof can significantly stimulate bile acid membrane receptor TGR5, promote the secretion of glucagon-like peptide 1 from enteroendocrine cells, reduce liver fat accumulation, significantly improve liver function and increase glucose tolerance, thereby having an excellent effect on the treatment of fatty liver disease.
    Type: Application
    Filed: August 24, 2020
    Publication date: September 1, 2022
    Inventors: Wei Jia, Guoxiang Xie, Ning Zhai, Aihua Zhao, Xiaojiao Zheng
  • Publication number: 20220026398
    Abstract: The present invention discloses a quantitative detection method of multiple metabolic components in a biological sample and a metabolic chip used in the method. The detection method includes performing derivatization treatment on the biological sample and then detecting the derivatized biological sample by liquid chromatography-mass spectrometry. During derivatization treatment, 3-nitrophenylhydrazine is used as a derivatization reagent, and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide is used as a derivatization reaction catalyst. According to the detection method of the present invention, high-sensitivity detection can be achieved, multiple metabolic components of different magnitudes can be detected, the operation is simple and fast, and the method is applicable to clinical detection and scientific research examination.
    Type: Application
    Filed: October 21, 2019
    Publication date: January 27, 2022
    Applicant: Human Metabolomics Institute Inc.
    Inventors: Wei JIA, Guoxiang XIE, Lu WANG